BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.33M | -69.90M | -68.21M | -50.95M | -40.06M |
| Total Depreciation and Amortization | 282.00K | 300.00K | 303.00K | 305.00K | 307.00K |
| Total Amortization of Deferred Charges | 1.80M | 1.65M | 1.41M | 1.07M | 774.00K |
| Total Other Non-Cash Items | 8.88M | 6.27M | 5.77M | -8.98M | -22.35M |
| Change in Net Operating Assets | 6.99M | 4.06M | 2.52M | 2.79M | -5.03M |
| Cash from Operations | -57.38M | -57.62M | -58.21M | -55.77M | -66.36M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.11M | -- | -2.50M | -2.50M | -2.50M |
| Issuance of Common Stock | 52.63M | 58.14M | 59.38M | 21.62M | 26.95M |
| Repurchase of Common Stock | -16.00K | -17.00K | -63.00K | -47.00K | -55.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -962.00K | -1.61M | -1.67M | -999.00K | -1.16M |
| Cash from Financing | 43.55M | 56.52M | 55.15M | 18.07M | 23.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.83M | -1.10M | -3.07M | -37.70M | -43.13M |